BioPharma Dive December 19, 2025
Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies that generated nearly $450 million over the first nine months of this year.
BioMarin Pharmaceutical has agreed to buy Amicus Therapeutics in a $4.8 billion deal that would hand it two marketed drugs for rare diseases and a third asset in late-stage human testing.
The all-cash acquisition, announced Friday, has BioMarin paying $14.50 for each Amicus share, or a 33% premium to the latter’s closing stock price on Thursday. The deal has unanimous support from the boards of both companies, and should close sometime between April and June next year.
BioMarin expects Amicus’ medicines to increase its long-term revenue...
Today's Sponsors
Today's Sponsor